Ritter Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, RTTR, Ritter Pharmaceuticals Inc, priceseries

Ritter Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
11.50
Close
11.20
High
13.50
Low
11.00
Previous Close
11.00
Daily Price Gain
0.20
YTD High
55.00
YTD High Date
Jun 24, 2015
YTD Low
0.15
YTD Low Date
Dec 26, 2019
YTD Price Change
-38.40
YTD Gain
-77.42%
52 Week High
55.00
52 Week High Date
Jun 24, 2015
52 Week Low
0.15
52 Week Low Date
Dec 26, 2019
52 Week Price Change
-38.40
52 Week Gain
-77.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
28.90
Jan 4. 2017
30.35
1 Trading Days
5.02%
Link
LONG
Oct 26. 2017
3.69
Oct 27. 2017
3.92
1 Trading Days
6.26%
Link
LONG
Mar 23. 2018
3.08
Mar 26. 2018
3.25
1 Trading Days
5.52%
Link
LONG
Apr 17. 2018
3.21
Apr 19. 2018
3.45
2 Trading Days
7.29%
Link
LONG
May 21. 2018
3.32
May 22. 2018
3.54
1 Trading Days
6.78%
Link
LONG
Jun 24. 2019
0.91
Jul 9. 2019
1.05
10 Trading Days
14.85%
Link
Company Information
Stock Symbol
RTTR
Exchange
NasdaqCM
Company URL
http://www.ritterpharmaceuticals.com
Company Phone
310-203-1000
CEO
Michael D. Step
Headquarters
California
Business Address
1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES, CA 90067
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001460702
About

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28, which is reduces the symptoms associated with lactose intolerance. The company was founded by Ira E. Ritter and Andrew J. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Description

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. The company's RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Its RP-G28 has been studied in a Phase 2b/3 clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading